Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Kyung-Sang Yu, Byungwook Kim, Dongseong Shin, Min Kyu Park, Jun Gi Hwang, Min-Gul Kim, Hyewon Chung, JongLyul Ghim, Jae-Yong Chung, Josef S. Smolen, Gerd R. Burmester, SungHyun Kim, YunJu Bae, DaBee Jeon, JaeKyoung Yoo, GoEun Yang, JiHun Bae & Edward Keystone. (2023) Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study. Expert Opinion on Investigational Drugs 32:5, pages 429-439.
Read now
Read now
Xiaoping Zhang, Ya-Chi Chen & Kimio Terao. (2017) Clinical pharmacology of tocilizumab for the treatment of polyarticular-course juvenile idiopathic arthritis. Expert Review of Clinical Pharmacology 10:5, pages 471-482.
Read now
Read now
Emma Mitchell & Graeme Jones. (2016) Subcutaneous tocilizumab for the treatment of rheumatoid arthritis. Expert Review of Clinical Immunology 12:2, pages 103-114.
Read now
Read now
Soken-Nakazawa J Song & Kazuyuki Yoshizaki. (2015) Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Expert Opinion on Drug Metabolism & Toxicology 11:2, pages 307-316.
Read now
Read now
Xiaoping Zhang, Peter N Morcos, Tomohisa Saito & Kimio Terao. (2013) Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis. Expert Review of Clinical Pharmacology 6:2, pages 123-137.
Read now
Read now
Zoe Ash & Paul Emery. (2012) The role of tocilizumab in the management of rheumatoid arthritis. Expert Opinion on Biological Therapy 12:9, pages 1277-1289.
Read now
Read now
Articles from other publishers (29)
Jumpei Saito, Naho Yakuwa, Yoshihiko Hosokawa, Hiromi Hamada, Tomo Suzuki, Haruhiko Sago, Kayoko Kaneko, Akimasa Yamatani & Atsuko Murashima. (2023) Establishment of a measurement system to evaluate breast milk transfer of biological agents using dry filter paper: a multi‐institutional study. British Journal of Clinical Pharmacology.
Crossref
Crossref
Beckey Trinh, Merel Peletier, Casper Simonsen, Peter Plomgaard, Kristian Karstoft, Bente Klarlund Pedersen, Gerrit van Hall & Helga Ellingsgaard. (2022) Amino Acid Metabolism and Protein Turnover in Lean and Obese Humans During Exercise—Effect of IL-6 Receptor Blockade. The Journal of Clinical Endocrinology & Metabolism 107:7, pages 1854-1864.
Crossref
Crossref
Funda TERZİ & Hüseyin Serkan EROL. (2022) Histopathological Examination of the Effects of Tocilizumab and Dexamethasone on the Liver in Rats of Oleic Acid induced Acute Lung Injury. Balıkesır Health Sciences Journal.
Crossref
Crossref
Matthew B Roberts & Jay A Fishman. (2021) Immunosuppressive Agents and Infectious Risk in Transplantation: Managing the “Net State of Immunosuppression”. Clinical Infectious Diseases 73:7, pages e1302-e1317.
Crossref
Crossref
Beckey Trinh, Merel Peletier, Casper Simonsen, Peter Plomgaard, Kristian Karstoft, Bente Klarlund Pedersen, Gerrit van Hall & Helga Ellingsgaard. (2021) Blocking endogenous IL-6 impairs mobilization of free fatty acids during rest and exercise in lean and obese men. Cell Reports Medicine 2:9, pages 100396.
Crossref
Crossref
Shervin Shokouhi, Saghar Barati, Neda Kazeminia, Faezeh Jamali, Baran Roshan & Zahra Sahraei. (2021) Evaluating the elimination status of medications used for COVID-19 during hemoperfusion and therapeutic plasma exchange: A review. International Immunopharmacology 97, pages 107707.
Crossref
Crossref
Parikshit Singh, S.K. Singh, Yadvir Garg, D.J. Gajbhiye, A.K. Jindal & Kavita Sahai. (2021) Characteristics, therapeutic modalities and outcomes of COVID-19 ventilated patients in a tertiary care hospital in counter-insurgency zone: Our experience. Medical Journal Armed Forces India 77, pages S345-S352.
Crossref
Crossref
Mauricio Cordero-Alfaro, Carlos León-Céspedes & Allan Ramos-Esquivel. (2021) Effectiveness of intravenous tocilizumab in routine clinical practice in a cohort of Costa Rican patients with rheumatoid arthritis. Reumatología Clínica (English Edition) 17:6, pages 329-334.
Crossref
Crossref
Mauricio Cordero-Alfaro, Carlos León-Céspedes & Allan Ramos-Esquivel. (2021) Efectividad del tocilizumab intravenoso en la práctica clínica usual de una cohorte de pacientes costarricenses con artritis reumatoide. Reumatología Clínica 17:6, pages 329-334.
Crossref
Crossref
Manjola BalliuLaura CalabresiNiccolò Bartalucci, Simone Romagnoli, Laura Maggi, Rossella Manfredini, Matteo Lulli, Paola Guglielmelli & Alessandro Maria Vannucchi. (2021)
Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for,
CALR
-mutated MPNs
. Blood Advances 5:8, pages 2184-2195.
Crossref
Crossref
Pascal Richette, Augustin Latourte, Jérémie Sellam, Daniel Wendling, Muriel Piperno, Philippe Goupille, Yves-Marie Pers, Florent Eymard, Sébastien Ottaviani, Paul Ornetti, René-Marc Flipo, Bruno Fautrel, Olivier Peyr, Jean Pierre Bertola, Eric Vicaut & Xavier Chevalier. (2021) Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial. Annals of the Rheumatic Diseases 80:3, pages 349-355.
Crossref
Crossref
Haleh Rezaee, Fariba Pourkarim, Samira Pourtaghi‐Anvarian, Taher Entezari‐Maleki, Touraj Asvadi‐Kermani & Masoud Nouri‐Vaskeh. (2021) Drug‐drug interactions with candidate medications used for COVID‐19 treatment: An overview. Pharmacology Research & Perspectives 9:1.
Crossref
Crossref
Elisa H Ignatius, Kunbo Wang, Andrew Karaba, Matthew Robinson, Robin K Avery, Paul Blair, Natasha Chida, Tania Jain, Brent G Petty, Zishan Siddiqui, Michael T Melia, Paul G Auwaerter, Yanxun Xu & Brian T Garibaldi. (2021) Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis. Open Forum Infectious Diseases 8:1.
Crossref
Crossref
Tülün ÖZTÜRK, Tuğba ÇAVUŞOĞLU, Canet İNCİR & Yeşim TUNÇOK. (2020) Interactions between Cytokines and Drugs in COVID-19 Potential Interactions between Increased Cytokines in COVID-19 and Drugs used to Treat COVID-19COVİD-19 da Sitokinler ve COVİD- 19 Tedavisinde Kullanılan İlaçlar Arasında Potansiyel İlaç Etkileşimleri.. Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi 8:1, pages 174-185.
Crossref
Crossref
Eric Toussirot, Hubert Marotte, Denis Mulleman, Grégoire Cormier, Fabienne Coury, Philippe Gaudin, Emmanuelle Dernis, Christine Bonnet, Richard Damade, Jean-Luc Grauer, Tassadit Ait Abdesselam, Caroline Guillibert-Karras, Frédéric Lioté, Pascal Hilliquin, Antoinette Sacchi, Daniel Wendling, Benoît Le Goff, Marc Puyraveau & Gilles Dumoulin. (2020) Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study. Arthritis Research & Therapy 22:1.
Crossref
Crossref
Marie Lund Bay, Sarah Heywood, Anne‐Sophie Wedell‐Neergaard, Tim Schauer, Louise Lang Lehrskov, Regitse Højgaard Christensen, Grit Elster Legård, Peter Østrup Jensen, Rikke Krogh‐Madsen & Helga Ellingsgaard. (2020) Human immune cell mobilization during exercise: effect of IL‐6 receptor blockade. Experimental Physiology 105:12, pages 2086-2098.
Crossref
Crossref
Louise L Lehrskov, Sasha Kjeldsen, Mark P Lyngbæk, Regitse Højgaard Chirstensen, Anne-Sophie Wedell-Neergaard, Line Søderlund, Niklas Rye Jørgensen, Rikke Krogh-Madsen, Nicolai J Wewer Albrechtsen & Helga Ellingsgaard. (2020) Interleukin-6 May Not Affect Bone Resorption Marker CTX or Bone Formation Marker P1NP in Humans. Journal of the Endocrine Society 4:9.
Crossref
Crossref
Eddie W. Fakhouri, Stephen J. Peterson, Janish Kothari, Ragin Alex, Joseph I. Shapiro & Nader G. Abraham. (2020) Genetic Polymorphisms Complicate COVID-19 Therapy: Pivotal Role of HO-1 in Cytokine Storm. Antioxidants 9:7, pages 636.
Crossref
Crossref
Jonathan B. Lamano, Jason Balquidera Lamano, Yuping D. Li, Joseph D. DiDomenico, Winward Choy, Dorina Veliceasa, Daniel E. Oyon, Shayan Fakurnejad, Leonel Ampie, Kartik Kesavabhotla, Rajwant Kaur, Gurvinder Kaur, Dauren Biyashev, Dusten J. Unruh, Craig M. Horbinski, C. David James, Andrew T. Parsa & Orin Bloch. (2019) Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth. Clinical Cancer Research 25:12, pages 3643-3657.
Crossref
Crossref
Michihiro Yabe, Kei Ishibashi, Akifumi Onagi, Ryo Tanji, Ruriko Honda-Takinami, Tomoyuki Koguchi, Kanako Matsuoka, Seiji Hoshi, Junya Hata, Masao Kataoka, Soichiro Ogawa, Hiroyuki Hiraki, Nobuhiro Haga & Yoshiyuki Kojima. (2018) Suppression of SOCS3 enhances TRAIL-induced cell growth inhibition through the upregulation of DR4 expression in renal cell carcinoma cells. Oncotarget 9:60, pages 31697-31708.
Crossref
Crossref
Andrea Rubbert-Roth, Daniel E. Furst, Jan Michael Nebesky, Angela Jin & Erhan Berber. (2018) A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases. Rheumatology and Therapy 5:1, pages 21-42.
Crossref
Crossref
Hisham Abdallah, Joy C. Hsu, Peng Lu, Scott Fettner, Xiaoping Zhang, Wendy Douglass, Min Bao, Lucy Rowell, Gerd R. Burmester & Alan Kivitz. (2017) Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA. The Journal of Clinical Pharmacology 57:4, pages 459-468.
Crossref
Crossref
Gerd R Burmester, William F Rigby, Ronald F van Vollenhoven, Jonathan Kay, Andrea Rubbert-Roth, Ariella Kelman, Sophie Dimonaco & Nina Mitchell. (2016) Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Annals of the Rheumatic Diseases 75:6, pages 1081-1091.
Crossref
Crossref
Kosmas Kretsos, Georg Golor, Astrid Jullion, Matthew Hickling, Suzanne McCabe, Stevan Shaw, Joby Jose & Ruth Oliver. (2014) Safety and pharmacokinetics of olokizumab, an anti‐IL‐6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study. Clinical Pharmacology in Drug Development 3:5, pages 388-395.
Crossref
Crossref
Shuji Ohta, Tomomi Tsuru, Kimio Terao, Seiji Mogi, Midori Suzaki, Eisuke Shono, Yoshimasa Ishida, Eriko Tarumi & Masato Imai. (2013) Mechanism‐based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). The Journal of Clinical Pharmacology 54:1, pages 109-119.
Crossref
Crossref
James E. Frampton. (2013) Tocilizumab: A Review of Its Use in the Treatment of Juvenile Idiopathic Arthritis. Pediatric Drugs 15:6, pages 515-531.
Crossref
Crossref
Xiaoping Zhang & Barbara J. Brennan. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
16
.
Toshiki Oguro, Kei Ishibashi, Takashi Sugino, Koichi Hashimoto, Shintaro Tomita, Norio Takahashi, Tomohiko Yanagida, Nobuhiro Haga, Ken Aikawa, Tatsuo Suzutani, Osamu Yamaguchi & Yoshiyuki Kojima. (2013) Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression. European Journal of Cancer 49:7, pages 1715-1724.
Crossref
Crossref
G. Wu, N. Chai, Irene Kim, A.S. Klein & S.C. Jordan. (2013) Monoclonal anti-interleukin-6 receptor antibody attenuates donor-specific antibody responses in a mouse model of allosensitization. Transplant Immunology 28:2-3, pages 138-143.
Crossref
Crossref